logo-loader
viewe-Therapeutics PLC

e-Therapeutics surges as it begins experimental testing of coronavirus treatment compounds

The firm believes the initial compound set has the potential to address both viral replication and the associated excessive immune response caused by the pathogen

e-Therapeutics PLC - e-Therapeutics surges as it begins experimental testing of coronavirus treatment compounds

e-Therapeutics PLC (LON:ETX) shares rose on Monday as the firm said it has begun experimental testing on the first set of compounds for the treatment of coronavirus (COVID-19) identified using its proprietary network-driven drug discovery (NDD) platform.

The AIM-listed firm said the initial compound set, which it believes has the potential to address both viral replication and the associated excessive immune response, will be tested by WuXi AppTec utilising its relevant cell-based assays.

READ: e-therapeutics appoints former Silence Therapeutics executive as its chief business officer

e-Therapeutics added that it will continue to pursue an NDD approach to identify approved and known drugs that could be “rapidly repositioned” for the treatment of coronavirus.

“Importantly, we are focusing on therapeutic strategies that target host systems, therefore minimising the risk of resistance and potentially being effective for the treatment of other viral conditions”, the company said.

"I am pleased to report progress on our contribution to the fight against [coronavirus], advancing from the computational stage of our project into experimental work. We are pursuing a multipronged effort for this project and will continue to provide updates as further data becomes available", e-Therapeutics executive chairman Ali Mortazavi said in a statement

e-Therapeutics shares surged 13.5% higher to 17.4p in early trading on Monday.

Quick facts: e-Therapeutics PLC

Price: 12 GBX

AIM:ETX
Market: AIM
Market Cap: £38.69 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of e-Therapeutics PLC named herein, including the promotion by the Company of e-Therapeutics PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: FTSE 100 makes early rally as airline losses set to total...

Headlines from the Proactive UK newsroom. The FTSE 100 rallied early on after two days of losses with travel groups leading the way. The blue-chip index was up 30 points at 6,366. Airline losses will total around US$84bn this year according to the International Air Transport Association....

on 10/6/20

2 min read